PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 26177348-0 2015 Comparison of tacrolimus and cyclosporin A in CYP3A5 expressing Chinese de novo kidney transplant recipients: a 2-year prospective study. Cyclosporine 29-42 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 46-52 26271661-2 2015 CYP3A5*3, CYP3A4*1B and CYP3A4*22 alleles of liver grafts may explain about one third of the inter-individual differences in pharmacokinetics of ciclosporin and tacrolimus in recipients. Cyclosporine 145-156 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 0-6 26271661-6 2015 RESULTS: The recipients with grafts from normal CYP3A4 expresser donors carrying CYP3A5*3/*3 required CNI maintenance doses more or less similar to the bodyweight-controlled starting doses (9.1 mg kg(-1) of ciclosporin and 0.1 mg kg(-1) of tacrolimus). Cyclosporine 207-218 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 81-87 25976223-0 2015 CYP3A4*18B and CYP3A5*3 polymorphisms contribute to pharmacokinetic variability of cyclosporine among healthy Chinese subjects. Cyclosporine 83-95 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 15-21 25976223-10 2015 CONCLUSIONS: The results indicate that gender and polymorphism in CYP3A4*18B and CYP3A5*3 significantly affect cyclosporine pharmacokinetics in healthy subjects. Cyclosporine 111-123 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 81-87 26177348-1 2015 AIMS: To assess the efficacy and safety of tacrolimus and cyclosporin A (CsA)-based immunosuppressive regimens in Chinese de novo kidney transplant recipients who are CYP3A5 expressers. Cyclosporine 73-76 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 167-173 26177348-15 2015 CONCLUSIONS: Cyclosporin A-based maintenance therapy is safe for Chinese de novo kidney transplant recipients who are CYP3A5 expressers. Cyclosporine 13-26 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 118-124 24691060-0 2014 Association of CYP3A4*18B and CYP3A5*3 polymorphism with cyclosporine-related liver injury in Chinese renal transplant recipients. Cyclosporine 57-69 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 30-36 25975003-6 2015 Among CYP3A5 substrates are cyclosporine and tacrolimus prescribed after organ transplantations. Cyclosporine 28-40 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 6-12 24658827-1 2014 PURPOSE: Tacrolimus (Tac) and cyclosporine (CsA) are mainly metabolized by CYP3A4 and CYP3A5. Cyclosporine 30-42 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 86-92 24658827-1 2014 PURPOSE: Tacrolimus (Tac) and cyclosporine (CsA) are mainly metabolized by CYP3A4 and CYP3A5. Cyclosporine 44-47 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 86-92 24691060-1 2014 OBJECTIVE: The purpose of this study was to investigate the associations between CYP3A4*18B and CYP3A5*3 polymorphism and cyclosporine-related liver injuries in Chinese renal transplant recipients. Cyclosporine 122-134 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 96-102 24527031-3 2014 Cytochrome P-450 isoenzymes CYP3A4 and CYP3A5 and protein P-glycoprotein (P-gp) are involved in CyA bioavailability. Cyclosporine 96-99 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 39-45 24369269-3 2014 Before initiation of triple therapy, all patients switched from tacrolimus to cyclosporine, which has a lower inhibitory effect on CYP3A4 and CYP3A5 than tacrolimus. Cyclosporine 78-90 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 142-148 23557867-10 2013 CONCLUSIONS: Genetic polymorphisms of CYP3A5*3 and CYP3A4*18B may be partly responsible in large interindividual variability of cyclosporine and tacrolimus blood levels in Chinese renal transplant patients during the first month after transplantation. Cyclosporine 128-140 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 38-44 23217392-4 2012 Retrospective case control study was utilized to identify the association between CYP3A4 1G, CYP3A5 3, ABCB1 genetic polymorphisms and CsA-related outcomes. Cyclosporine 135-138 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 93-99 23085740-7 2012 RESULTS: The CYP3A5*3C polymorphism influenced the C(0) and C(0)/dose of CsA, which were significantly higher in patients with the GG genotype than in patients with the AA or GA genotypes. Cyclosporine 73-76 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 13-19 23085740-10 2012 In the multiple regression model, CYP3A5*3C, age, hemoglobin and blood creatinine level were associated with the log-transformed CsA C(0)/dose. Cyclosporine 129-132 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 34-40 23085740-11 2012 CONCLUSION: CYP3A5*3C correlates with the C(0)/dose of CsA on the seventh day after renal transplantation. Cyclosporine 55-58 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 12-18 22205779-0 2012 Cyclosporine A- and tacrolimus-mediated inhibition of CYP3A4 and CYP3A5 in vitro. Cyclosporine 0-14 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 65-71 22947591-0 2012 CYP3A5 polymorphism effect on cyclosporine pharmacokinetics in living donor renal transplant recipients: analysis by population pharmacokinetics. Cyclosporine 30-42 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 0-6 22947591-13 2012 A population pharmacokinetic analysis showed that postoperative days, sex, and CYP3A5 genotype significantly affected the pharmacokinetics of cyclosporine. Cyclosporine 142-154 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 79-85 22947591-15 2012 CONCLUSIONS: Using the present model to calculate the dose of cyclosporine with CYP3A5 genotyping can be possible for the patients whose cyclosporine concentration is not within the therapeutic range even with therapeutic drug monitoring. Cyclosporine 62-74 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 80-86 22947591-15 2012 CONCLUSIONS: Using the present model to calculate the dose of cyclosporine with CYP3A5 genotyping can be possible for the patients whose cyclosporine concentration is not within the therapeutic range even with therapeutic drug monitoring. Cyclosporine 137-149 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 80-86 23018254-0 2012 Impact of CYP3A4*1B and CYP3A5*3 polymorphisms on the pharmacokinetics of cyclosporine and sirolimus in renal transplant recipients. Cyclosporine 74-86 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 24-30 23018254-9 2012 The mean cyclosporine dose in CYP3A5*1/*3 subjects was 400.65+-164.97 mg/day vs. 263.52+-64.39 mg/day in CYP3A5*3/*3 subjects (p<0.022). Cyclosporine 9-21 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 30-36 23018254-11 2012 CONCLUSIONS: Genetic polymorphisms in CYP3A4 and CYP3A5 may underlie inter-individual differences in cyclosporine pharmacokinetics after renal transplantation. Cyclosporine 101-113 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 49-55 23018254-12 2012 Patients with at least 1 functional CYP3A5*1 or CYP3A4*1B allele require significantly higher doses of cyclosporine to reach target drug levels compared to patients with the CYP3A4*1 or CYP3A5*3 alleles. Cyclosporine 103-115 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 36-42 22205779-4 2012 The aim of this study was to investigate the inhibitory effect and inhibition characteristics of CsA and Tac on CYP3A4 and CYP3A5 in vitro and to evaluate its clinical relevance. Cyclosporine 97-100 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 123-129 22205779-5 2012 Inhibition by CsA and Tac was studied using midazolam as the probe substrate in coincubation and preincubation investigations using human liver microsomes (HLMs) as well as specific CYP3A4- and CYP3A5-expressing insect microsomes (Supersomes). Cyclosporine 14-17 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 194-200 21896346-6 2012 The CYP3A5 +6986AA genotype was associated with a high cyclosporine blood level after transplantation. Cyclosporine 55-67 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 4-10 21896346-11 2012 Although the CYP3A5 +6986AA genotype was correlated with a high blood cyclosporine concentration, lack of the MDR1 +1236CC genotype in both the donor and recipient was correlated with less TRM and a longer OS in patients who received allogeneic HSCT. Cyclosporine 70-82 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 13-19 21806386-1 2011 AIM: Polymorphisms in the CYP3A5 and ABCB1 genes have been investigated as modulators of the pharmacokinetics and clinical effects of cyclosporine (CSA) and tacrolimus (TAC) in European, North American and Asian populations, with controversial results. Cyclosporine 134-146 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 26-32 21806386-1 2011 AIM: Polymorphisms in the CYP3A5 and ABCB1 genes have been investigated as modulators of the pharmacokinetics and clinical effects of cyclosporine (CSA) and tacrolimus (TAC) in European, North American and Asian populations, with controversial results. Cyclosporine 148-151 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 26-32 20214406-7 2010 For patients prescribed ciclosporin, the CYP3A5 6986A>G SNP may influence long-term survival, possibly because of a different metabolite pattern over time. Cyclosporine 24-35 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 41-47 21839244-0 2011 Pharmacogenetic study of ABCB1 and CYP3A5 genes during the first year following heart transplantation regarding tacrolimus or cyclosporine levels. Cyclosporine 126-138 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 35-41 21839244-3 2011 We evaluated the SNPs in ABCB1 (glycoprotein P) and CYP3A5 (metabolic enzyme) genes, seeking correlate them with tacrolimus or cyclosporine levels during the first year after heart transplantation. Cyclosporine 127-139 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 52-58 20368718-0 2011 The effect of CYP3A5 polymorphism on dose-adjusted cyclosporine concentration in renal transplant recipients: a meta-analysis. Cyclosporine 51-63 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 14-20 20368718-1 2011 Cyclosporine (CsA) is a substrate of cytochrome P450 (CYP) 3A5 and has a narrow therapeutic range with large inter-individual variability. Cyclosporine 0-12 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 37-62 21383650-1 2011 BACKGROUND: The association of CYP3A5, CYP3A4, and ABCB1 single nucleotide polymorphisms (SNPs) with cyclosporine (CsA) pharmacokinetics is controversial. Cyclosporine 101-113 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 31-37 21383650-1 2011 BACKGROUND: The association of CYP3A5, CYP3A4, and ABCB1 single nucleotide polymorphisms (SNPs) with cyclosporine (CsA) pharmacokinetics is controversial. Cyclosporine 115-118 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 31-37 21857093-0 2011 Influence of ABCB1, CYP3A4*18B and CYP3A5*3 polymorphisms on cyclosporine A pharmacokinetics in bone marrow transplant recipients. Cyclosporine 61-75 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 35-41 21857093-1 2011 The aim of this study was to retrospectively evaluate the effect of polymorphisms in the CYP3A4, CYP3A5 and ABCB1 genes on the dose-adjusted concentration and dose requirement of cyclosporine A(CsA) in Chinese recipients during the early period after bone marrow or hematopoietic stem cell transplantation. Cyclosporine 179-193 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 97-103 21102498-5 2011 The CsA concentration was significantly higher when the genotype of CYP3A5 rs15524 was T/T (P=0.044) or rs776746 was G/G (P=0.027). Cyclosporine 4-7 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 68-74 21857093-5 2011 Compared with CYP3A5*3/*3 individuals, CYP3A5*1/*1 subjects have a significantly lower dose-adjusted C0 and C2 at days 1-10 and a higher dose requirement for CsA at days 16-30 (p < 0.05). Cyclosporine 158-161 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 39-45 20588203-0 2010 Effects of the CYP3A5*3 variant on cyclosporine exposure and acute rejection rate in renal transplant patients: a meta-analysis. Cyclosporine 35-47 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 15-21 20588203-1 2010 BACKGROUND: Whether the loss-of-function allele CYP3A5*3 variant is associated with significantly impaired metabolism of cyclosporine A (CsA) in transplant patients is still controversial because of the lack of prospective, large-scale clinical studies performed among diversely ethnic populations. Cyclosporine 121-135 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 48-54 20170205-8 2010 Influence of the CYP3A5 6986A>G SNP on the pharmacokinetics of ciclosporin is also uncertain and likely to be small. Cyclosporine 66-77 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 17-23 20170205-9 2010 CYP3A4 may play a more dominant role than CYP3A5 in the metabolism of ciclosporin. Cyclosporine 70-81 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 42-48 20038391-1 2009 OBJECTIVE: To determine how single nucleotide polymorphisms located on genes MDR1, CYP3A4 and CYP3A5 affect the absorption kinetics of cyclosporine in cardiac transplant patients. Cyclosporine 135-147 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 94-100 19925383-11 2009 MDR1 haplotypes and CYP3A5*3 genotypes can be related to C(2) and C(0) of CsA, respectively. Cyclosporine 74-77 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 20-26 19667964-8 2009 Cyclosporine A and Tac are metabolized by CYP3A4 and CYP3A5, and several single nucleotide polymorphisms in the two genes have been associated with differences in drug clearance. Cyclosporine 0-14 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 53-59 19925383-0 2009 Influence of the MDR1 haplotype and CYP3A5 genotypes on cyclosporine blood level in Chinese renal transplant recipients. Cyclosporine 56-68 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 36-42 19925383-1 2009 The purpose of the study was to elucidate the influence of multidrug resistance gene (MDR1) haplotype and CYP3A5 genotype on cyclosporine (CsA) blood level in Chinese renal transplant recipients. Cyclosporine 125-137 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 106-112 19376366-0 2009 Genetic polymorphisms in CYP3A5 and MDR1 genes and their correlations with plasma levels of tacrolimus and cyclosporine in renal transplant recipients. Cyclosporine 107-119 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 25-31 19343327-3 2009 The dose-adjusted levels were significantly lower in CYP3A5 expressers for CsA (p = 0.037; 3 months) and Tac (p < 0.001; 1 month and p < 0.001; 3 months) compared to the non-expressers, suggesting that for a given dose their CsA/Tac blood concentration is lower. Cyclosporine 75-78 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 53-59 18936931-0 2009 Effect of genetic polymorphisms of CYP3A5 and MDR1 on cyclosporine concentration during the early stage after renal transplantation in Chinese patients co-treated with diltiazem. Cyclosporine 54-66 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 35-41 18978522-4 2008 CYP3A5 expressors (*1/*3 genotype; n = 8-10) presented significantly lower dose-adjusted cyclosporine trough concentrations (P < 0.05) and required significantly higher daily doses per weight (P < 0.01) than the nonexpressors (*3/*3 genotype; n = 55-59) 1, 3, 6, and 12 months after transplantation. Cyclosporine 89-101 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 0-6 18180803-0 2008 CYP3A5 genotype is associated with longer patient survival after kidney transplantation and long-term treatment with cyclosporine. Cyclosporine 117-129 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 0-6 18180803-1 2008 The CYP3A5*1 allele has been linked to high expression of CYP3A5 and metabolism of cyclosporine. Cyclosporine 83-95 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 4-10 18978522-5 2008 In addition, 7 days after transplantation, more CYP3A5 expressors had uncorrected trough cyclosporine concentration below the target concentration of 200 ng/mL than the nonexpressors (odds ratio = 7.2; 95% confidence interval = 1.4-37.3; P = 0.009). Cyclosporine 89-101 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 48-54 18978522-8 2008 In conclusion, CYP3A4, CYP3A5, and CYP3A7 polymorphisms affect cyclosporine metabolism, and therefore, their genotyping could be useful, in association with therapeutic drug monitoring, to prospectively optimize cyclosporine prescription in transplant recipients. Cyclosporine 63-75 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 23-29 18978522-8 2008 In conclusion, CYP3A4, CYP3A5, and CYP3A7 polymorphisms affect cyclosporine metabolism, and therefore, their genotyping could be useful, in association with therapeutic drug monitoring, to prospectively optimize cyclosporine prescription in transplant recipients. Cyclosporine 212-224 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 23-29 18589174-3 2008 Frequencies of CYP3A5*1 versus *3 and MDR1-C3435T were correlated with tacrolimus (TAC) and cyclosporine (CSA) concentration-to-dose (C/D) ratios. Cyclosporine 92-104 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 15-21 18636247-0 2008 Association of MDR1, CYP3A4*18B, and CYP3A5*3 polymorphisms with cyclosporine pharmacokinetics in Chinese renal transplant recipients. Cyclosporine 65-77 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 37-43 18636247-11 2008 Large prospective studies may be needed to further explore the impact of MDR1 and CYP3A5*3 polymorphisms on CsA pharmacokinetics in renal transplant recipients. Cyclosporine 108-111 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 82-88 19005401-1 2008 BACKGROUND: Bioavailability of tacrolimus (Tac) and cyclosporine is determined by cytochrome P450IIIA and by P-glycoprotein encoded by the CYP3A4/CYP3A5 and ABCB1 genes. Cyclosporine 52-64 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 146-152 18518855-7 2008 In adults, genetic polymorphisms in the genes encoding the cyclosporine-metabolizing enzymes CYP3A4 and CYP3A5, as well as the ABCB1 gene, which encodes the efflux-pump P-glycoprotein, seem to have a limited effect, if any, on cyclosporine pharmacokinetics. Cyclosporine 59-71 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 104-110 18589174-3 2008 Frequencies of CYP3A5*1 versus *3 and MDR1-C3435T were correlated with tacrolimus (TAC) and cyclosporine (CSA) concentration-to-dose (C/D) ratios. Cyclosporine 106-109 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 15-21 17151193-8 2007 A deeper inhibitory effect of cyclosporine on the CL(int) of sirolimus depletion was found for rCYP 3A4 than for rCYP 3A5 (i.e., -44% versus -8% at 0.62 microM, 750 microg/l cyclosporine), and sirolimus metabolism was slightly less inhibited for HLMs expressing CYP 3A5 than not (-38% versus -56%). Cyclosporine 30-42 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 114-121 18240909-5 2007 The association between the CYP3A4 and CYP3A5 polymorphisms and cyclosporine pharmacokinetics is more questionable. Cyclosporine 64-76 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 39-45 17425754-5 2007 Significant differences (of a magnitude unlikely to be relevant clinically) in dose-normalized blood ciclosporin concentrations were found only between MDR-1 genotypes of the C1236T SNP and between haplotype groups C-G-C and T-T-T in patients that were expressers of CYP3A5. Cyclosporine 101-112 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 267-273 16827636-0 2006 Association between cyclosporine concentration and genetic polymorphisms of CYP3A5 and MDR1 during the early stage after renal transplantation. Cyclosporine 20-32 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 76-82 16759707-5 2006 Both tacrolimus and cyclosporine are substrates of Pgp, CYP3A4 and CYP3A5, and therefore, these molecules are potential pharmacokinetic factors with which to establish personalized dosage regimens for these drugs. Cyclosporine 20-32 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 67-73 17049128-1 2006 AIM: To investigate whether the CYP3A5*3 polymorphism would affect cyclosporine A (CsA) metabolism in Chinese renal transplant patients. Cyclosporine 83-86 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 32-38 17042920-0 2006 Effects of genetic polymorphisms of CYP3A4, CYP3A5 and MDR1 on cyclosporine pharmacokinetics after renal transplantation. Cyclosporine 63-75 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 44-50 17042920-7 2006 The aim of the present study was to evaluate retrospectively the effects of genetic polymorphisms of CYP3A4, CYP3A5 and MDR1 on cyclosporine dose adjusted trough blood concentration during the early period after renal transplantation in Chinese patients. Cyclosporine 128-140 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 109-115 17042920-14 2006 The median cyclosporine dose-adjusted C(0) in CYP3A5*1/*1 genotype subjects (n = 6) was 14.8 ng/mL per mg per kg (range 11.1-26.8 ng/mL per mg per kg), in CYP3A5*1/*3 patients (n = 34) it was 23.7 ng/mL per mg per kg (range 9.0-61.0 ng/mL per mg per kg) and for CYP3A5*3/*3 patients (n = 66) it was 26.4 ng/mL per mg per kg (range 9.8-85.8 ng/mL per mg per kg; P = 0.012, Kruskal-Wallis test). Cyclosporine 11-23 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 46-52 17042920-15 2006 Accordingly, cyclosporine dose-adjusted C0 was larger in CYP3A5 non-expressors than expressors in the first week after renal transplantation. Cyclosporine 13-25 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 57-63 17042920-18 2006 In conclusion, the present study shows that genetic polymorphisms in CYP3A5 may be responsible, in part, for the large interindividual variability of cyclosporine pharmacokinetics during the early phase after renal transplantation in Chinese patients. Cyclosporine 150-162 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 69-75 17042920-19 2006 Patients with the CYP3A5*3 variant genotype require a low dose of cyclosporine to reach target levels compared with those with the CYP3A5*1 allele. Cyclosporine 66-78 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 18-24 16430309-10 2006 In the case of midazolam, ciclosporin, nifedipine and docetaxel, clearance by individuals with a CYP3A5-expressing genotype did not differ from that for nonexpressors, but in the case of tacrolimus, eight independent studies have demonstrated faster clearance by those carrying one or two CYP3A5*1 alleles. Cyclosporine 26-37 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 97-103 16612333-4 2006 The objective of our study is to determine correlation if any between single-nucleotide polymorphisms of CYP3A5 and CYP3AP1 on cyclosporine dose requirement and concentration-to-dose ratio in renal allograft recipients. Cyclosporine 127-139 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 105-111 16612333-5 2006 Cyclosporine-dependent renal allograft recipients were genotyped for CYP3A5 A6986G and CYP3AP1 G-44A. Cyclosporine 0-12 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 69-75 16612333-9 2006 Patients with *1*1*1*1 (n=5) CYP3A5- and CYP3AP1-linked genotypes needed higher dose of cyclosporine compared to patients with *1*3*1*3 (n = 27) and *3*3*3*3 (n = 33) linked genotypes in months 3 and 6 post-transplantation (P < 0.016). Cyclosporine 88-100 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 29-35 16612333-10 2006 The identification of patients with *1*1*1*1 by CYP3A5 and CYP3AP1 genotyping may have a clinically significant and positive impact on patient outcome with reduced rejection rate by providing pretransplant pharmacogenetic information for optimization of cyclosporine A dosing. Cyclosporine 254-268 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 48-54 15808586-0 2005 Genetic polymorphisms of CYP3A5 genes and concentration of the cyclosporine and tacrolimus. Cyclosporine 63-75 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 25-31 15723604-5 2005 The association between the CYP3A4 and CYP3A5 polymorphisms and cyclosporine pharmacokinetics is more questionable. Cyclosporine 64-76 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 39-45 15808586-2 2005 Our objective was to determine the relationship between genetic polymorphisms of CYP3A5 with respect to interindividual variability in CsA and tacrolimus pharmacokinetics. Cyclosporine 135-138 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 81-87 15450954-1 2004 The objectives of this study were to characterize and compare the metabolic profile of cyclosporine A (CsA) catalyzed by CYP3A4, CYP3A5 and human kidney and liver microsomes, and to evaluate the impact of the CYP3A5 polymorphism on product formation from parent drug and its primary metabolites. Cyclosporine 103-106 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 129-135 15450954-5 2004 Microsomes isolated from human kidney produced only AM9 and the rate of product formation (2 and 20 microM CsA) was positively associated with the detection of CYP3A5 protein and presence of the CYP3A5*1 allele in 4 of the 20 kidneys tested. Cyclosporine 107-110 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 160-166 15450954-5 2004 Microsomes isolated from human kidney produced only AM9 and the rate of product formation (2 and 20 microM CsA) was positively associated with the detection of CYP3A5 protein and presence of the CYP3A5*1 allele in 4 of the 20 kidneys tested. Cyclosporine 107-110 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 195-201 15450954-9 2004 AM19 and AM1c9, two of the major secondary metabolites of CsA, were produced by CsA, AM1 and AM1c when incubated with CYP3A4, CYP3A5, kidney microsomes from CYP3A5*1/*3 donors and all liver microsomes. Cyclosporine 58-61 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 126-132 15450954-9 2004 AM19 and AM1c9, two of the major secondary metabolites of CsA, were produced by CsA, AM1 and AM1c when incubated with CYP3A4, CYP3A5, kidney microsomes from CYP3A5*1/*3 donors and all liver microsomes. Cyclosporine 58-61 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 157-163 15450954-9 2004 AM19 and AM1c9, two of the major secondary metabolites of CsA, were produced by CsA, AM1 and AM1c when incubated with CYP3A4, CYP3A5, kidney microsomes from CYP3A5*1/*3 donors and all liver microsomes. Cyclosporine 80-83 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 126-132 15450954-9 2004 AM19 and AM1c9, two of the major secondary metabolites of CsA, were produced by CsA, AM1 and AM1c when incubated with CYP3A4, CYP3A5, kidney microsomes from CYP3A5*1/*3 donors and all liver microsomes. Cyclosporine 80-83 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 157-163 15450954-11 2004 Together, the data demonstrate that CYP3A5 may contribute to the formation of primary and secondary metabolites of CsA, particularly in kidneys carrying the wild-type CYP3A5*1 allele. Cyclosporine 115-118 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 36-42 15450954-11 2004 Together, the data demonstrate that CYP3A5 may contribute to the formation of primary and secondary metabolites of CsA, particularly in kidneys carrying the wild-type CYP3A5*1 allele. Cyclosporine 115-118 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 167-173 15454731-0 2004 The effect of variable CYP3A5 expression on cyclosporine dosing, blood pressure and long-term graft survival in renal transplant patients. Cyclosporine 44-56 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 23-29 15454731-1 2004 OBJECTIVE: Cyclosporine is extensively metabolized by cytochrome-P450 3A (CYP3A) enzymes in the liver and intestine including the CYP3A5 isoenzyme. Cyclosporine 11-23 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 130-136 15454731-4 2004 We tested whether the presence of the CYP3A5*1 allele in renal transplant recipients and in donor kidneys influences cyclosporine dose requirements, blood pressure and long-term graft survival in renal transplant patients during chronic treatment with a cyclosporine-based immunosuppressive regimen. Cyclosporine 117-129 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 38-44 15454731-4 2004 We tested whether the presence of the CYP3A5*1 allele in renal transplant recipients and in donor kidneys influences cyclosporine dose requirements, blood pressure and long-term graft survival in renal transplant patients during chronic treatment with a cyclosporine-based immunosuppressive regimen. Cyclosporine 254-266 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 38-44 12817518-3 2003 Our objective was to evaluate the effect of CYP3A5 and MDR1 polymorphic expression on CsA oral disposition. Cyclosporine 86-89 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 44-50 15167702-4 2004 The objective of this study was to investigate the effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood concentrations in stable transplant patients. Cyclosporine 102-114 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 61-67 12966368-0 2003 Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Cyclosporine 112-124 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 37-43 12966368-3 2003 OBJECTIVE: Our objective was to determine the role of genetic polymorphisms in CYP3A4, CYP3A5, and MDR-1 with respect to interindividual variability in cyclosporine and tacrolimus pharmacokinetics. Cyclosporine 152-164 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 87-93 35202484-2 2022 Genetic variation within the CYP3A5 gene locus impacts the metabolism of several clinically important drugs, including the immunosuppressants tacrolimus, sirolimus, cyclosporine, and the benzodiazepine midazolam. Cyclosporine 165-177 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 29-35 12673034-3 2003 In this study, we demonstrated the inductive effects of phenobarbital, rifampicin, carbamazepine, phenytoin, prednisolone, ciclosporin and clotrimazole on CYP3A4, CYP3A5 and CYP3A7 mRNA expression, and established the relationship between the expression of human glucocorticoid receptor alpha (hGR) mRNA and the induction of CYP3A4 mRNA in cultured HepG2 cells by reverse transcription polymerase chain reaction (RT-PCR). Cyclosporine 123-134 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 163-169 12673034-7 2003 Treatment with phenytoin, rifampicin, carbamazepine and ciclosporin induced approximately 2-fold increases in the expression of CYP3A5 mRNA, although prednisolone, phenytoin and clotrimazole had no effect. Cyclosporine 56-67 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 128-134 10837558-3 1997 There is also evidence that cyclosporine is metabolized to a lesser extent by cytochrome P450 3A5 (CYP3A5). Cyclosporine 28-40 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 78-97 10837558-3 1997 There is also evidence that cyclosporine is metabolized to a lesser extent by cytochrome P450 3A5 (CYP3A5). Cyclosporine 28-40 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 99-105 35629245-6 2022 SNPs in CYP3A5*3 were significantly associated with greater dose-adjusted cyclosporine and tacrolimus concentrations. Cyclosporine 74-86 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 8-14 31385766-0 2019 Association Between CYP3A4 and CYP3A5 Genotypes and Cyclosporine"s Blood Levels and Doses among Jordanian Kidney Transplanted Patients BACKGROUND: Cyclosporine is used as an immunosuppressive agent in kidney transplantation. Cyclosporine 147-159 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 31-37 30520827-0 2019 Switching Immunosuppression From Cyclosporine to Tacrolimus in Kidney Transplant Recipients Based on CYP3A5 Genotyping. Cyclosporine 33-45 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 101-107 32162881-9 2020 RESULTS: The patient carried CYP3A5*3 GG genotype and the concentration of cyclosporine remained steady in the period of conversion and combination of cyclosporine and posaconazole. Cyclosporine 75-87 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 29-35 32162881-9 2020 RESULTS: The patient carried CYP3A5*3 GG genotype and the concentration of cyclosporine remained steady in the period of conversion and combination of cyclosporine and posaconazole. Cyclosporine 151-163 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 29-35 30378493-12 2019 CYP3A families, especially CYP3A4 and CYP3A5, play an important role in the biotransformation of CsA. Cyclosporine 97-100 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 38-44 31385766-2 2019 Cyclosporine is predominantly metabolized by CYP3A4 and CYP3A5. Cyclosporine 0-12 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 56-62 31385766-3 2019 The most commonSingle Nucleotide Polymorphisms (SNPs) affecting cyclosporine metabolism (CYP3A4*1B, CYP3A4*1G,CYP3A4*22 and CYP3A5*3) were investigated among Jordanian kidney transplanted patients to find out the genotypesand allele frequencies of these SNPs. Cyclosporine 64-76 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 124-130 29113387-3 2017 Meanwhile, the dose of FK506 and CsA was recorded, blood concentration of the drugs was measured, and graft outcome was monitored.These results indicate that CYP3A5*AA/AG carriers need higher FK506 dose than CYP3A5*GG homozygote to achieve the target blood concentration. Cyclosporine 33-36 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 158-164 29135906-0 2017 Effect of Age and Allele Variants of CYP3A5, CYP3A4, and POR Genes on the Pharmacokinetics of Cyclosporin A in Pediatric Renal Transplant Recipients From Serbia. Cyclosporine 94-107 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 37-43 29135906-3 2017 The aim of this study was to assess the impact of age, CYP3A5*3, CYP3A4*22, and POR*28 alleles on CsA pharmacokinetics in pediatric renal transplant recipients. Cyclosporine 98-101 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 55-61 29135906-8 2017 Carriers of CYP3A5*3 allele aged <=6 years required higher dose of CsA and achieved lower C0/dose and C2/dose, at most time points, than older carriers of this allele. Cyclosporine 70-73 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 12-18 29135906-12 2017 CONCLUSIONS: Younger age, POR*28 allele, and CYP3A5*3 allele were associated with higher CsA dosing requirements and lower concentration/dose ratio. Cyclosporine 89-92 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 45-51 29113387-4 2017 For CYP3A5*GG carriers, taking FK506 or CsA are both advisable. Cyclosporine 40-43 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 4-10 29113387-6 2017 CYP3A5 genotyping is a new approach to detecting FK506 dose requirement and a predictive index for the FK506 or CsA treatment selection in kidney recipients. Cyclosporine 112-115 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 0-6 29441922-0 2016 The impact of CYP3A5 on the metabolism of cyclosporine A and tacrolimus in the evaluation of efficiency and safety of immunosuppressive treatment in patients after kidney transplantation. Cyclosporine 42-56 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 14-20 29441922-1 2016 The aim of the study was to determine the impact of CYP3A5 mutation on the serum levels of immunosuppressive drugs (tacrolimus and cyclosporine A), and on the occurrence of acute rejection episodes among patients after kidney transplantation. Cyclosporine 131-145 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 52-58 27310200-8 2016 Cyclosporine predominantly inhibited CYP3A4 (half maximal inhibitory concentration = 0.71 microM) rather than CYP3A5 (>5 microM), whereas tacrolimus showed similar inhibition for CYP3A4 (0.29 microM) and CYP3A5 (0.41 microM). Cyclosporine 0-12 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 207-213 27653228-4 2016 RESULTS: Expression of CYP3A5 by either or both the donor and the recipient was significantly associated with lower Tac, but not CsA, dose-normalized trough levels. Cyclosporine 129-132 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 23-29